Rodríguez, Carmen
Jara-Palomares, Luis
Tabernero, Eva
Tenes, Andrés
González, Sara
Briceño, Winnifer
Lobo, José Luis
Morillo, Raquel
Bikdeli, Behnood
Jiménez, David
Article History
Received: 17 January 2022
Accepted: 14 February 2022
First Online: 3 March 2022
Declarations
:
: The institutional review board at each of the participating sites approved the protocol, and each patient provided written informed consent.
: Not applicable.
: C.R. has nothing to disclose.L.J-P. has served as an advisor or consultant for Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Leo Pharma, Menarini, Pfizer, and ROVI.E.T. has nothing to disclose.A.T. has nothing to disclose.S.G. has nothing to disclose.W.B. has nothing to disclose.J.L.L. has nothing to disclose.R.M. has nothing to disclose.B.B. reports that he serves as a consulting expert (on behalf of the plaintiff) for litigation related to two specific brand models of inferior vena caval filters.D.J. has served as an advisor or consultant for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, Pfizer, ROVI and Sanofi; served as a speaker or a member of a speakers’ bureau for Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Leo Pharma, ROVI and Sanofi; received grants for clinical research from Daiichi Sankyo, Sanofi and ROVI.